Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication.

Ahimastos AA, Latouche C, Natoli AK, Reddy-luthmoodoo M, Golledge J, Kingwell BA.

Circ Res. 2014 Mar 28;114(7):1144-55. doi: 10.1161/CIRCRESAHA.114.302420. Retraction in: Circ Res. 2015 Sep 11;117(7):e64.

2.

Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.

Ahimastos AA, Walker PJ, Askew C, Leicht A, Pappas E, Blombery P, Reid CM, Golledge J, Kingwell BA.

JAMA. 2013 Feb 6;309(5):453-60. doi: 10.1001/jama.2012.216237. Retraction in: JAMA. 2015 Oct 13;314(14):1520-1.

3.

Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication.

Shahin Y, Cockcroft JR, Chetter IC.

Br J Surg. 2013 Aug;100(9):1154-63. doi: 10.1002/bjs.9198.

PMID:
23842829
5.

Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial.

Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA.

Ann Intern Med. 2006 May 2;144(9):660-4. Retraction in: Ann Intern Med. 2015 Dec 1;163(11):884.

PMID:
16670135
6.

Ramipril improves walking times and quality of life in patients with stable intermittent claudication.

Brittenden J.

Evid Based Med. 2014 Feb;19(1):16. doi: 10.1136/eb-2013-101301. No abstract available.

PMID:
23842688
7.

Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results.

Verma S, Lonn EM, Nanji A, Browne K, Ward R, Robertson A, Conradson H, Hildebrand K, Brant R, Anderson TJ.

Can J Cardiol. 2009 Jul;25(7):e236-40.

8.

ACP Journal Club. Ramipril improved walking times and QOL in peripheral artery disease and intermittent claudication.

Jaar BG.

Ann Intern Med. 2013 Jun 18;158(12):JC7. doi: 10.7326/0003-4819-158-12-201306180-02007. No abstract available.

PMID:
23778931
9.

Effects of oral N-acetylcysteine on walking capacity, leg reactive hyperemia, and inflammatory and angiogenic mediators in patients with intermittent claudication.

da Silva ND Jr, Roseguini BT, Chehuen M, Fernandes T, Mota GF, Martin PK, Han SW, Forjaz CL, Wolosker N, de Oliveira EM.

Am J Physiol Heart Circ Physiol. 2015 Sep;309(5):H897-905. doi: 10.1152/ajpheart.00158.2015.

10.

Summaries for patients. Ramipril improves walking ability in patients with peripheral arterial disease.

[No authors listed]

Ann Intern Med. 2006 May 2;144(9):I24. No abstract available. Retraction in: Ann Intern Med. 2015 Dec 1;163(11):884.

PMID:
16670129
11.

The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.

O'Donnell ME, Badger SA, Sharif MA, Makar RR, McEneny J, Young IS, Lee B, Soong CV.

Eur J Vasc Endovasc Surg. 2009 Mar;37(3):326-35. doi: 10.1016/j.ejvs.2008.11.028.

12.

Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease.

Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J.

Eur J Vasc Endovasc Surg. 2005 Feb;29(2):171-6.

13.

PURLs: ramipril for claudication?

Stephens LA, Rogers N, Stevermer JJ.

J Fam Pract. 2013 Oct;62(10):579-80. Retraction in: J Fam Pract. 2016 Nov;65(11):754.

14.

Ramipril for treatment of intermittent claudication.

Poredos P.

Vasa. 2013 Jul;42(4):237-8. doi: 10.1024/0301-1526/a000284. No abstract available.

PMID:
23823855
16.

Effect of ramipril on renal function in patients with intermittent claudication.

Hobbs SD, Claridge MW, Wilmink AB, Adam DJ, Thomas ME, Bradbury AW.

Vasc Health Risk Manag. 2008;4(2):471-5.

17.

Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication.

Shahin Y, Barnes R, Barakat H, Chetter IC.

Atherosclerosis. 2013 Dec;231(2):283-90. doi: 10.1016/j.atherosclerosis.2013.09.037.

PMID:
24267241
18.

Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.

De Jager J, Kooy A, Lehert P, Bets D, Wulffelé MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD.

J Intern Med. 2005 Jan;257(1):100-9.

19.

Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients.

Ahimastos AA, Dart AM, Lawler A, Blombery PA, Kingwell BA.

J Hypertens. 2008 May;26(5):1037-42. doi: 10.1097/HJH.0b013e3282f8e3b6. Retraction in: J Hypertens. 2015 Dec;33(12):2552.

PMID:
18398348

Supplemental Content

Support Center